PMS30 SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE TURKISH PAYER PERSPECTIVE
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.1574
https://www.valueinhealthjournal.com/article/S1098-3015(19)33952-X/fulltext
Title :
PMS30 SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE TURKISH PAYER PERSPECTIVE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33952-X&doi=10.1016/j.jval.2019.09.1574
First page :
Section Title :
Open access? :
No
Section Order :
11365